slas sbs orlandoconference prelim program

Gaylord Palms Resort and Convention Center

March 27–31, 2011 | Orlando, Florida, USA

SLAS.org/events/sbs11

Preliminary ProgramRegister by January 24 for Maximum Savings!

2 | SLAS.org/events/sbs11

Welcome Page 3

Schedule-at-a-Glance Page 4

What’s New and Exciting for SBS 2011 Page 6

Short Course Program Overview Page 7

Keynote Speakers Page 10

Technical Session Program Overview Page 11

Special Educational Sessions Page 15

SLAS Career Connections Page 15

Special Interest Groups (SIGs) Page 16

Exhibition Page 17

General Information Page 19

Social Events and Networking 0

Registration Form Page 21

SBS 2011 Scientific Committee, SLAS Board of Directors, BSS Executive Council, LAS Executive Council Page 23

Sponsors and Media Partners Back Cover

Table of Contents

SLAS.org/events/sbs11 | 3

Dear Colleagues, On behalf of the Society for Laboratory Automation and Screening (SLAS), we invite you to join us at the 17th Annual SBS Conference and Exhibition in Orlando, Florida. We are proud to host this exciting event, which includes:

Engaging• keynote presentations by SBS Achievement Award winner Robert J. Lefkowitz, SBS Accomplishment Award winner Brian Shoichet, and Professor Hugh Rosen of The Scripps Research Institute

An • outstanding scientific program and thought-provoking poster presentations

An exhibit floor • thriving with leading companies from around the world

Informative• vendor tutorials and collaborative Special Interest Groups (SIGs)

Innovative• new programs and awards

Most importantly, SBS 2011 provides a place for you to come together with other scientists, engineers and professionals involved in the science of drug discovery and screening to learn, and share ideas, research and innovation.

As a conference participant, you may choose from 15 diverse scientific sessions organized in three tracks, with each session punctuated by a keynote presentation:

Track I: Innovations in the Screening SciencesThis track captures the excitement of recent advances in all aspects of the screening sciences, with a focus on innovations in instrumentation, reagents and technologies that are impacting “HTS to Lead” efforts.

Track II: Translational ResearchThese sessions describe the changing face of drug discovery in the 21st century and introduce collaborative paradigms and resources that enhance translational research.

Track III: Sequenced Genomes: Reducing Opportunities to PracticeThis track explores how the availability of sequenced genomes and the inevitability of inexpensive phenotyping are impacting therapeutic agent and consumer product discovery. And most importantly, these sessions illustrate how screening sciences are ideally positioned to take advantage of these opportunities.

Collectively, the range of offerings this year enables participants to remain at the forefront of emerging capabilities in this field. SBS 2011 is an event you won’t want to miss—we look forward to seeing you in Orlando!

Paul Bernasconi and Peter Hodder SBS 2011 Program Chairs


Schedule-at-a-Glance* | New and Improved Hours!

8:30 am – 5:00 pm Short CoursesAutomated Assays for Drug Discovery: A Toolbox Approach to Selecting an »Appropriate Assay

BacMam101: Practical Aspects of Making and Using BacMam Vectors »

Establishing Cell-Based Assays for Screening »

In Vitro ADME Screening: Basic Concepts and Practical Methods »

Label-Free/Biophysics Methods for Screening »

Statistical Methods for In Vitro Assays in Drug Discovery »

High-Content Screening »

9:00 am – 12:00 pm Exhibitor Workshops

1:00 – 4:00 pm BioAssay Ontology: Development of an Industry Standard for the Description and Categorization of Small Molecule High-Throughput Screening Data

1:30 – 4:30 pm Exhibitor Workshops

9:00 – 11:00 am Opening Session/Keynote Address

11:00 am – 6:30 pm Exhibit Hall Open

11:30 am – 1:00 pm Poster Session 1 and Lunch in the Exhibit Hall

1:30 – 4:30 pm Technical SessionsTrack I: Session 1: SLAS Session: Next Generation Technologies: Microfluidics »

Track II: Session 1: Translational Research: Resources and Collaborative Paradigms »in Academia, Not-for-Profit and Industry

Track III: Session 1: Target Resuscitation: Drug Repositioning Opportunities »

5:00 – 6:30 pm Welcome Reception in the Exhibit Hall

* Schedule Subject to Change

8:00 – 8:45 am Exhibitor Tutorials

9:00 am – 12:00 pm Technical SessionsTrack I: Session 2: Innovations in Screening Biology: Assays, Techniques »and Instrumentation

Track II: Session 2: Government, Foundation, NGO and Industry Funded Research »Initiatives

Track III: Session 2: Target Mining:Interpretation and Annotation, Data Analysis, »Deorphaning

12:00 – 4:30 pm Exhibit Hall Open

12:00 – 1:30 pm Poster Session 2 and Lunch in the Exhibit Hall

12:30 – 1:15 pm Exhibitor Tutorials

2:00 – 4:00 pm Special Interest Groups (SIGs)


Sunday, March 27

Monday, March 28

Tuesday, March 29


9:00 am – 12:00 pm Technical SessionsTrack I: Session 5: Innovations in Screening and Sample Management: Technologies »and Processes

Track II: Session 5: Translational Research »

Track III: Session 5: Prediction and Elucidation of Target Liabilities »

12:00 – 1:30 pm Closing Luncheon and Keynote Presentation

8:00 – 8:45 am Exhibitor Tutorials

9:00 am – 12:00 pm Technical SessionsTrack I: Session 3: Critical Reagents and Technologies in HTS to Lead Efforts »

Track II: Session 3: Molecular Discovery in Non-Traditional, Neglected »and Rare Diseases

Track III: Session 3: Applications in Consumer Products, Cosmetics, Nutraceuticals »and Agriculture

12:00 – 5:30 pm Exhibit Hall Open

12:00 – 1:30 pm Poster Session 3 and Lunch in the Exhibit Hall


2:00 – 4:30 pm Technical SessionsTrack I: Session 4: Innovations in Label Free, Multiplexed and High Content Assays »

Track II: Session 4: Case Studies for HotTargets: From the Lab to Lead Compounds »

Track III: Session 4: Tools for Drug Target Validation: RNAi, cDNA, Peptides and »Structural Biology

4:30 – 5:30 pm Reception in the Exhibit Hall

7:00 – 10:00 pm Conference Networking Reception at Gaylord Palms Hotel

Thursday, March 31

Wednesday, March 30

Join the SLAS Social Media CommunitiesOur online communities are growing every day. Stay up-to-date and join in the discussions. Sign-up now!


What’s New and Exciting for SBS 2011

During this five-day event more than 2,000 scientists, innovators, researchers and industry analysts from around the globe gather in Orlando to learn about the latest trends and basic and applied research that are transforming the way new pharmaceuticals are developed.

SBS 2011 offers:15 Diverse Scientific Sessions Organized Into Three Tracks: •

Innovations in the Screening Sciences »

Translational Research »

Sequenced Genomes: Reducing Opportunities to Practice »

Engaging Keynote Presentations •

SBS Achievement Award winner Robert J. Lefkowitz, M.D., Duke University, and SBS Accomplishment Award winner Brian Shoichet, Ph.D., University of California, San Francisco, and Hugh Rosen, M.D., Ph.D., The Scripps Research Institute

Enhanced Exhibit Hall Hours and Schedule•

Allows for a thriving exhibit floor with leading companies from around the world.

SLAS Smart-Savers Discount Program•

Offers extraordinary discounts on flights, registration, hotel accommodations, and more.

Enhanced SLAS Career Connections•

Provides a forum for job seekers and employers to connect, and career coaches offering free coaching services to participants by appointment.

SLAS New Product Award Designation•

Recognizes up to three of the best and most promising new products launched on the exhibit floor.


Short Course Program Overview

Sunday, March 27 8:30 am – 5:00 pmAutomated Assays for Drug Discovery: A Toolbox Approach to Selecting an Appropriate Assay This course focuses on one central question: given a multitude of assay technologies available for a given target, how does one go about selecting an appropriate technology? What criteria should one examine during this process? This course describes a toolbox approach—a generic, flexible set of assay methodologies and shows how they can be applied to some of the major target classes in molecular and cell-based screening. Assay case studies are presented, and course participants will engage in discussions of toolbox formats comparing the robustness of different assays as well as cost and user-friendliness.

ObjectivesThis course reviews various state-of-the-art assay and detection technologies available for development and implementation of molecular and cell-based assays for accelerated drug discovery. Emphasis is placed on generic assay formats that can be applied to a variety of target types—the Assay Toolbox. Specifically, it provides theoretical background and best practices for the design, development and implementation of automated assays for kinases, proteases, GPCRs, protein-protein interactions, receptor-ligand binding, and other target classes of interest.

Who Would Benefit From This CourseIndividuals involved in assay development at any level.

InstructorsE. Michael August, Boehringer-Ingelheim Pharmaceuticals, Inc. (Lead instructor); Mohammed Kashem, Boehringer-Ingelheim Pharmaceuticals, Inc.; Siqi Lin, Boehringer-Ingelheim Pharmaceuticals, Inc.

BacMam101: Practical Aspects of Making and Using BacMam VectorsBacMam engineered recombinant baculovirus vectors can efficiently deliver expression cassettes to a wide variety of mammalian cell types. The ease of generation, the safety and the unparalleled experimental versatility of BacMam vectors makes transient gene delivery in support of cell-based assays a viable option for high-throughput screening. This course covers basic practical aspects of vector generation and provides detailed instruction on how to optimally utilize BacMam vectors for development and support of cell-based assays. There is plenty of time available during the class for discussion as well as Q&A. The course describes the basic principles of viral generation, insect cell culture and recombinant baculovirus growth procedures as well as provides details of how to develop BacMam based assays.

ObjectivesSpecific objectives of this course include: 1. Introduction to Baculovirus and design of recombinant baculoviral vectors 2. Methods for production of recombinant baculoviral vectors 3. BacMam assay design and optimization 4. Biosafety of BacMam vectors 5. Commercially available BacMam resources

Who Would Benefit From This CourseCurrent users of the technology as well as those wishing to learn how they might implement BacMam technology in their own laboratory would benefit from this course.

InstructorsRobert Ames, GlaxoSmithKline (Lead Instructor); Frederick M. Boyce, Massachusetts General Hospital; Jim Fornwalkd, GlaxoSmithKline; Patrick Condreay, GlaxoSmithKline; Christopher Kemp, Kempbio, Inc.; George Handsen, Life Technologies

The SBS 2011 Short Course Program offers rapid introduction to, or relevant refresher on, important drug discovery topics. Led by distinguished faculty with deep expertise in their respective course topic, SBS short courses offer practical training. Held on Sunday prior to the Monday opening of the main technical program, participants can attend the short course program without missing a moment of the 17th Annual SBS Conference and Exhibition.

Short Courses are not included in the full conference registration fee. For short course pricing see page 22.



Establishing Cell-Based Assays for ScreeningCell-based assays are essential tools in the drug-discovery industry. They are important in high-throughput screening as well as target identification and secondary compound profiling. Selecting the most appropriate assay from the large number available and establishing that assay within a minimal time frame are critical to a project’s success. This course begins with an overview of critical factors to consider for selection, maintenance, and characterization of cells necessary to develop successful cell-based assays for HTS.

Specific application examples covered by individual instructors include: 1. An overview of cell viability, cytotoxicity, and apoptosis assays including multiplexing with genetic reporters 2. The scale-up and use of frozen cells for GPCR assays such as cAMP, cellular reporters, calcium mobilization or label-free electrical impedance measurements 3. An overview of the application and use of RNAi technology for screening

ObjectivesThe course objective includes teaching the student the basic strategy and methodology for conducting cell-based assays and providing a toolbox for picking assays appropriate for a particular need based on evaluations of the advantages and disadvantages of each method.

Who Would Benefit From This CourseAll levels from beginner to intermediate to advanced developing cell-based assays for screening.

InstructorTerry Riss, Promega Corporation (Lead Instructor)

In Vitro ADME Screening: Basic Concepts and Practical Methods This course covers principles and methods of in vitro ADME (Absorption, Distribution, Metabolism and Excretion) testing. Selected topics include solubility, plasma protein binding, absorption including Caco-2, metabolic stability, cytochrome P450 inhibition and induction.

ObjectivesAttendees of this course gain an understanding of basic concepts and methods for in vitro ADME testing. In addition, attendees learn how to interpret test findings, with the aim of selecting small molecule drug candidates with favorable pharmacokinetic properties. The merits of selected common and more recent approaches are examined.

Who Would Benefit From This CourseIndividuals with little or no exposure to ADME concepts benefit from this course. More experienced individuals seeking “refresher” training or exposure to alternate views also benefit. Expected participants include synthetic chemists, nonclinical and clinical scientists, individuals from regulatory agencies and project team leaders.

InstructorsCharles L. Crespi, Becton Dickinson and Company (Lead Instructor); Anshul Gupta, AstraZeneca; Michael Rooney, AstraZeneca; David Stresser, BD Biosciences

Label-Free/Biophysics Methods for Screening Biophysical/label-free methods are becoming important tools in lead finding and drug discovery, complementing, but not replacing, more classical assay technologies. A collection of long-standing, “gold-standard” label-free methods is rapidly being augmented by novel, higher throughput techniques, presenting both an extensive but also confusing landscape of biophysics tools in drug discovery. A key question is how to enable efficient and more systematic use of the biophysics portfolio in early drug-discovery programs. Ultimately they are expected to offer not only novel ways of hit finding, but also more efficient ways to identify and advance true hits for chemistry and later stage biology. This course focuses on biophysics technologies with highest impact and applicability for screening and lead finding (e.g., protein thermal denaturation and aggregation [DSF aka Thermofluor, DSLS aka Stargazer, Atlas]; SPR, interferometry and waveguide grating [e.g. SPR aka Biacore, Corning Epic, SRU BIND, Fortebio]; NMR; calorimetry (DSC, ITC); affinity mass spectrometry; dynamic light scattering.

ObjectivesProvide an overview on the most relevant biophysics/label-free technologies for screening and lead finding. This course includes teaching the basic strategy of the technologies, discussing key applications in screening/lead finding projects and their use in the light of impact but also limitations. Showcases help the attendee to better judge how to make best use of this quite novel technology toolbox in their individual projects.

Who Would Benefit From This CourseIndividuals interested in getting an overview about the current broad biophysics/label-free portfolio in lead finding, but certainly all persons involved in the field who want to learn about concepts and applications of their “best practice.” This course is directed towards attendees from both industry and academia. However, due to the vast variety of potential label-free methods and applications, the focus is on technologies suitable in a typical screening/lead-finding environment of early drug discovery.

InstructorJohannes Ottl, Novartis Pharma NIBR


Statistical Methods for In Vitro Assays in Drug Discovery The course covers a set of statistical methods that are useful for designing, optimizing, validating, and analyzing in vitro biological assays for use in drug-discovery research. Covered topics will include Z’factor, false positive/negative rates, dose-response curve fitting, minimum significant ratio, control charting, correlation, and statistical experimental design.

ObjectivesUpon completion of this course, participants are able to: 1. Understand and apply common assay performance measures 2. Calculate false positive and false negative rates for high-throughput screening assays 3. Understand and apply appropriate statistical methods for estimating potency values 4. Determine the reproducibility of potency assays using the minimum significant ratio (MSR) and control charting 5. Apply correlation analysis to understand flow scheme connectivity 6. Understand the basic concepts of statistical experimental design for optimizing assays

Who Would Benefit From This CourseThis course is targeted to individuals interested in developing in vitro biological assays and use of these assays in drug discovery.

InstructorViswanath Devanarayan, Abbott Laboratories, GPRD

High-Content ScreeningHigh-content screening is a powerful technology platform for implementing functional cell-based assays that allow truly multiparametric analysis in the physiological context of intact cells. This course provides a state-of-the-art overview of the components of HCS (instrumentation, fluorescent labels, HC assay development, automated image analysis and multi-parametric data analysis) together with some showcases of small molecule and RNAi high-content screens in industry and academia.

ObjectivesTeach the basics relevant to high-content screening and provide an overview on the toolbox (instrumentation, reagents, image and data analysis). Explore special aspects in assay development for HCS. Present showcases to discuss assay selection, screening and hit verification strategies.

Who Would Benefit From This CourseBoth beginners as well as experienced persons wishing to be refreshed on some aspects of HCS and more recent developments would greatly benefit. This course is directed towards attendees from both industry and academia.


Join SLAS and Save Big On SBS 2011Did you know that by becoming a member of SLAS and registering for SBS 2011 with the member discount, you will save significantly more money than you would if you registered for SBS 2011 as a non-member? Join SLAS now at SLAS.org and save big on SBS 2011!


Keynote Speakers

Thought-Provoking Keynote Presentations Thought-provoking presentations by impressive scientific pacesetters offer personal insights into innovation and achievement. Learn from them and be inspired by them.

Monday, March 28, 9:00 – 11:00 am

SBS Achievement Award WinnerRobert J. Lefkowitz, M.D., Duke University School of Medicine, Durham, North Carolina

Beta Arrestin Mediated Signaling by 7 Transmembrane Receptors: New Therapeutic OpportunitiesRobert J. Lefkowitz studies receptor biology and signal transduction and is best known for his detailed characterizations of the sequence, structure and function of the beta-adrenergic receptor and the proteins required for its regulation. Upon recognizing the sequence and functional homology with the visual protein rhodopsin, Dr. Lefkowitz proposed that adrenergic receptors and rhodopsin were related and the first members of a new protein family, the seven transmembrane receptors or G-protein coupled receptors. This superfamily is now known to be the largest, most diverse, and most therapeutically accessible. Author or co-author of more than 800 publications, Dr. Lefkowitz is among the most highly cited researchers in the fields of biology, biochemistry, pharmacology, toxicology, and clinical medicine according to Thomson-ISI.

SBS Accomplishment Award WinnerBrian Shoichet, Ph.D., University of California, San Francisco, San Francisco, California

Mechanism and Effects of Colloidal Aggregation in Early Discovery and Drug PharmacologyResearch in the Shoichet Lab at the University of California, San Francisco seeks to bring chemical reagents to biology, using a combination of computational simulation and experiment. Using a protein- centric approach, new ligands are sought to complement protein structures. This typically involves molecular docking and the development of model experimental systems to experimentally test new algorithms. A new direction adopts a ligand-centric approach that seeks new targets for known drugs and reagents. Whereas this lacks the physical foundation of structure-based docking, it returns to an older, pharmacological view of biological relationships, bringing to it a quantitative model. A biological focus for both areas is the discovery of reagents to modulate GPCRs. This research is supported by the National Institutes of Health.

Thursday, March 31, 12:00 – 1:30 pm

Hugh Rosen, M.D., Ph.D., The Scripps Research Institute, Scripps, Florida

Allostery and S1P Receptors: A Syzygy of Pharmacology and High-Resolution Crystal StructureApproaches to S1P1 receptor therapeutics will be presented, including uHTS approaches, pharmacological clues for allostery, pocket mapping by mutagenesis, insights from a high-resolution S1P1 crystal structure, implications for signal bias and the biological consequences of receptor modulation.


Monday, March 28

1:30 – 4:30 pm

Track I » Session 1: SLAS Session: Next Generation Technologies: MicrofluidicsSession Chairs: Bill Janzen, University of North Carolina at Chapel Hill and Scott Martin, St. Louis University

1:30 – 2:00 pm Plenary: Micro- and Nanofluidic Devices: Acquiring Chemical and Biochemical Information Quickly From Small Quantities of Material; Michael Ramsey, University of North Carolina, Chapel Hill

2:00 – 2:30 pm Enhanced Information From Microtiter Plate Screening by Scanning Wells Integrated Into Microfluidic Devices; Dana M. Spence, Michigan State University, United States

3:00 – 3:30 pm Micro- and Nanofluidic Devices for Cancer Screening and Virus Sensing; Stephen Jacobson, Indiana University

3:30 – 4:00 pm Perfusion Culture Microchamber Array Chip for High-Throughput Cell-Based Assays; Shinji Sugiura, National Institute of Advanced Industrial Science and Technology (AIST)

4:00 – 4:30 pm Well Plate Microfluidic Devices for Investigation of Dynamic Platelet Behavior Under Variable Shear Loads; Carolyn Conant, Fluxion Biosciences

1:30 – 4:30 pmTrack II » Session 1: Translational Research: Resources and Collaborative Paradigms in Academia, Not-for-Profit and IndustrySession Chair: Paul Burn, Sanford Research Center

1:30 – 2:00 pm Plenary: Putting Research Into Practice; Paul Burn, Sanford Research Center

2:00 – 2:30 pm Changing the Rules for the Research “Game” in Academia—Accelerating Discovery Through Novel Means of Collaboration; Mark Atkinson, The University of Florida

3:00 – 3:30 pm Collaboration as a Central Strategy for Successful Translational Research; John Reed, Sanford-Burnham Medical Research Institute

3:30 – 4:00 pmChallenges and Successes of Translational Research in the Public Domain: Retrospective and Prospective Analyses and Case Histories of “Probes to Leads” From Six Years of the Molecular Libraries Program; Stefan Vasile, Conrad Prebys Center for Chemical Genomics at Lake Nona

4:00 – 4:30 pm Translation in Action: MRCT's Centre for Therapeutics Discovery; Justin Bryans, MRC Technology

Track I: Innovations in the Screening SciencesTo stand still is to lose ground; innovation in High-Throughput Screening Technologies (HTS) is exploding. This track captures the excitement in all aspects of HTS. See what’s new in screening automation, instrumentation, detection technologies and sample management.

Track II: Translational ResearchWell established as an essential tool in industry, the screening sciences have been embraced by academic institutions, not-for-profit organizations, government-funded labs and non-government organizations (NGOs). These organizations complement the work done in industry or form cross-functional patnerships to achieve transcendent goals. Come and hear how this shift is changing research and the relations between industry, government and academia.

Track III: Sequenced Genomes: Reducing Opportunities to PracticeThe availability of sequenced genomes and the inevitability of inexpensive phenotyping have created huge opportunities in therapeutic agents and consumer products discovery. Come and share how and why screening sciences are ideally positioned to take advantage of these opportunities.

Please check the website often—SLAS.org/events/sbs11—for the most up-to-date information regarding SBS 2011 in Orlando.

Technical Session Program Overview

Schedule subject to change


1:30 – 4:30 pm Track III » Session 1: Target Resuscitation: Drug Repositioning OpportunitiesSession Chair: Roger Bosse, PerkinElmer

1:30 – 2:00 pmPlenary: Drug Repositioning: How it Fits With Current Drug-Discovery Trends; Christopher A. Lipinski, Melior Discovery

2:00 – 2:30 pmProdrugs: Regulatory and Clinical Development Requirements For Approval; Ken Phelps, Camargo Pharmaceutical Services, LLC

3:00 – 3:30 pm Michel Bouvier, University of Montreal

3:30 – 4:00 pmA Rapid Assay for Identifying New Drug Candidates From Approved Drugs for Repositioning to Treat Giardiasis; Catherine Chen, NIH Chemical Genomics Center

Tuesday, March 29

9:00 am – 12:00 pmTrack I » Session 2: Innovations in Screening Biology: Assays, Techniques and InstrumentationSession Chair: Jonathan O’Connell, Bristol-Myers Squibb Company

9:00 – 9:30 amPlenary: The Evolution of HTS at Bristol-Myers Squibb: Enabling the Support of the Most Relevant Bio-Assays; Jonathan O’Connell, Bristol-Myers Squibb Company

9:30 – 10:00 amEtv6-NTRK3, A Constitutively Active Tyrosine Kinase Found in Variety of Tumors, is Unique in its Mechanism of Transformation; Jack Allen, Merrimack Pharmaceuticals

10:30 – 11:00 amHigh-Throughput Screening With Real-Time PCR: Reducing it to Practice; Andrea Weston, Bristol-Myers Squibb Company

11:00 – 11:30 amNew Ion Channel Screening Technologies Enabling Development of High Quality and High-Throughput Assays in a Plate-Based Screening Group; Juha Kammonen, Pfizer

11:30 am – 12:00 pmCreating a Holistic Screening Strategy for Label-Free Technology in a Plate Based Screening Group; Rachel Russell, Pfizer Global Research & Development

9:00 am – 12:00 pmTrack II » Session 2: Government, Foundation, NGO and Industry Funded Research InitiativesSession Chair: Ken Duncan, Bill and Melinda Gates Foundation

9:00 – 9:30 amPlenary: Drug Discovery Focused on Neglected Diseases Through Initiatives Funded by Governments, Foundations and Private Donors; Ken Duncan, Bill and Melinda Gates Foundation

9:30 – 10:00 am The Importance of Metabolic Status to Tuberculosis Drug Discovery; Clifton Barry, NIAID, NIH

10:30 – 11:00 am Screening for Novel Antimalarials; R. Kip Guy, St. Jude Children’s Research Hospital

11:00 – 11:30 amCancer Research Technology: Bridging the Industry-Academia Interface in Oncology; Tim Hammonds, Cancer Research Technology

11:30 am – 12:00 pmSimultaneous Screening of a Large Natural Product Library Against a Panel of 10 Anti-Apoptotic Proteins in Search of Novel Cancer Therapeutics; Paul Diaz, Sanford-Burnham Medical Research Institute

9:00 am – 12:00 pmTrack III » Session 2: Target Mining: Interpretation and Annotation, Data Analysis, DeorphaningSession Chair: Andrew Su, Genomics Institute of the Novartis Research Foundation

9:00 – 9:30 amPlenary: The Gene Wiki: Crowdsourcing Knowledge Extraction From the Biomedical Literature; Andrew Su, Genomics Institute of the Novartis Research Foundation

9:30 – 10:00 amSystems and Personalized Medicine; Atul Butte, Stanford University and Lucile Packard Children’s Hospital

10:30 – 11:00 amCausal Reasoning on Biological Networks: Interpreting Transcriptional Changes; Daniel Ziemek, Pfizer Worldwide Research and Development

11:00 – 11:30 amDrug Effects Viewed From a Protein Network Perspective; William Loging, Ingelheim Pharmaceuticals, Inc.



Wednesday, March 30

9:00 am – 12:00 pmTrack I » Session 3: Critical Reagents and Technologies in HTS to Lead EffortsSession Chairs: Ulrich Schopfer, Novartis Institutes for BioMedical Research and Achim Grenz, F. Hoffman-La Roche Ltd

9:00 – 9:30 amPlenary: Bridging the Gap Between Phenotypic Screens and Molecular Targets; Ulrich Schopfer, Novartis Institute for BioMedical Research, Inc.

9:30 – 10:00 amIdentifying Helicobacter Pylori AddAB DNA Repair Enzyme Inhibitors Using a Novel Bacteriophage E. coli Infectivity Assay in Highly Miniaturized Formats; Tim Spicer, The Scripps Research Institute

10:30 – 11:00 amTarget Identification and Validation Using Chemical and Functional Genetics Screening Approaches; Vic Myer, Novartis Institutes for Biomedical Research, Inc.

11:00 – 11:30 amHT RNAi Screening of Anti-Cancer Targets With Pooled shRNA Libraries; Alex Chenchik, Cellecta, Inc.

11:30 am – 12:00 pmHuman “Knock-in” “Knock-out” Cell Lines for Precision Functional Genomics and Targeted Drug Discovery; Chris Torrance, Horizon Discovery Ltd, IQ Cambridge

9:00 am – 12:00 pmTrack II » Session 3: Molecular Discovery in Non-Traditional, Neglected and Rare DiseasesSession Chair: Bob Hertzberg, GlaxoSmithKline

9:00 – 9:30 amPlenary: Opening the Doors and Giving Back: GSK’s Strategy to Deliver Medicines for Diseases of the Developing Worlds; Bob Hertzberg, GlaxoSmithKline

9:30 – 10:00 amThroughput Screening to Identify Inhibitors of the Respiratory Chain of Mycobacterium Tuberculosis; Khisimuzi Mdluli, Global Alliance for TB Drug Development

10:30 – 11:00 amThe Development of RNA-Modulating Therapies; Judith C.T. van Deutekom, Prosensa Therapeutics BV, Leiden

11:00 – 11:30 amHumanitarian and Commercial Cloud-Based Collaborative Drug Discovery; Barry Bunin, Collaborative Drug Discovery (CDD), Inc.

11:30 am – 12:00 pmPotent and Selective Inhibitors of the Plasmodium Falciparum M18 Aspartyl Aminopeptidase (AAP) of Human Malaria Identified via a QFRET uHTS Campaign; Virneliz Fernandez Vega, The Scripps Research Institute, Scripps Florida

9:00 am – 12:00 pmTrack III » Session 3: Applications in Consumer Products, Cosmetics,Nutraceuticals and AgricultureSession Chair: Sabrina Corazza, Axxam

9:00 – 9:30 am Plenary: New Frontiers for HTS Application: How and Why; Sabrina Corazza, Axxam

9:30 – 10:00 am Receptor Mediated Discovery of Novel Taste Modulators; Jay Slack, Givaudan Flavors Corp.

10:30 – 11:00 amInsecticidal Compounds “Well” Spotted: Screening Live Bugs in a High-Throughput System;Juergen Langewald, BASF

11:00 – 11:30 am Anthony J. Clark, PepsiCo

2:00 – 4:30 pmTrack I » Session 4: Innovations in Label-Free, Multiplexed and High-Content AssaysSession Chair: James Inglese, NIH Chemical Genomics Center

2:00 – 2:30 pmPlenary: Quantitative High-Throughput Screening of Phenotypic Assays Enabled by Laser-Scanning-Coupled Microscopy; James Inglese, NIH Chemical Genomics Center

2:30 – 3:00 pm Jeffrey Price, Sanford Burnham

3:00 – 3:30 pmBinding Assays in Biological Liquids Using Microscale Thermophoresis; Stefan Duhr, NanoTemper Technologies

3:30 – 4:00 pmUse of Label-Free Technology to Monitor GPCR Desensitization; Patricia McDonald, Scripps Research Institute

4:00 – 4:30 pmEnabling Lead Discovery at Epigenetics Targets With RapidFire Mass Spectrometry; Melanie Leveridge, GlaxoSmithKline



2:00 – 4:30 pmTrack II » Session 4: Development of Novel Anti-Cancer Therapeutics that Reduce Tumor-Initiating Cell FrequencySession Chair: Phillip Tagari, Amgen

2:00 – 2:30 pm Plenary: Inhibitors of 2-OG Oxygenases for the Treatment of Anemia and Cancer; Phillip Tagari, Amgen

2:30 – 3:00 pm Cancer Drug Discovery: A Target Class Approach to Histone Methyltransferases; Mike Moyer, EpiZyme, Inc.

3:00 – 3:30 pm Identification and Characterization of Potent and Selective Antagonists of the Nuclear Receptor RORc; Gary Glick, Lycera Corporation

3:30 – 4:00 pm Targeting the Ubiquitin Pathway: Beyond the Proteasome; Craig Allan Leach, Progenra Inc.

4:00 – 4:30 pm Development of Novel Anti-Cancer Therapeutics that Reduce Tumor-Initiating Cell Frequency; Tim Hoey, OncoMed Pharmaceuticals, Inc.

2:00 – 4:30 pmTrack III » Session 4: Tools for Drug Target Validation: RNAi, cDNA, Peptides and Structural BiologySession Chair: Daniel Sipes, Genomics Institute of the Novartis Research Foundation

2:00 – 2:30 pm Expanding the Utility of Miniaturized HTS: From Screening to Profiling and Target Identification; Daniel Sipes, Genomics Institute of the Novartis Research Foundation

2:30 – 3:00 pm Technologies Recently Developed for the Determination of the Cellular Activity of Small Molecules; Frederick J. King, The Novartis Institutes for Biomedical Research

3:00 – 3:30 pm Now What? Approaches to Following Up Large-Scale Screening; John Hogenesch, University of Pennsylvania

3:30 – 4:00 pm Parallel Small-Scale Expression and ELT Screening of Drug Targets to Explore Druggability and Generate Chemical Probes; Jeffrey Gross, GlaxoSmithKline

4:00 – 4:30 pm Target Validation Strategies for Protease Research; Lorenz Mayr, Novartis Pharma AG

Thursday, March 31

9:00 am – 12:00 pmTrack I » Session 5: Innovations in Screening and Sample Management: Technologies and ProcessesSession Chair: Claude DuFresne, Merck

9:00 – 9:30 am Claude DuFresne, Merck

9:30 – 10:00 am The Impact of Non-Contact Picoliter Dispense Technology in the Elimination of Serial Dilution; Daniel Thomas, GlaxoSmithKline

10:30 – 11:00 am Labware Leachables: Do You Know What’s In Your Assay Well?; John Watson, Bristol-Myers Squibb R&D

11:00 – 11:30 am Investigating the Stability of High Concentration DMSO Solutions; Ioana Popa-Burke, GlaxoSmithKline

11:30 am – 12:00 pm The Optimization of Instrumentation, Workflow and Data Analysis for In Vitro ADME Assays: A Business Case; Thomas Arnhold, Boehringer Ingelheim Pharma GmbH and Co KG

9:00 am – 12:00 pm Track II » Session 5: Translational Research (Visit SLAS.org/events/sbs11 for speaker updates.)

9:00 am – 12:00 pm Track III » Session 5: Prediction and Elucidation of Target LiabilitiesSession Chair: Keith Houck, Environmental Protection Agency

9:00 – 9:30 am Plenary: Elucidation of Adverse Bioactivity Profiles as Predictors of Toxicity Potential; Keith Houck, Environmental Protection Agency

9:30 – 10:00 am Utilities of In Vitro Safety Pharmacology in Early Drug Discovery: Mitigation of ADRs; Laszlo Urban, Novartis Institutes for Biomedical Research

10:30 – 11:00 am From Data to Knowledge: Integration of Compound Structure and Activity With Clinical ADRs; Eugen Lounkine, Novartis Institutes for Biomedical Research

11:00 – 11:30 am In Silico Modeling for Predicting In Vivo Kinetics and Toxicity During Drug Discovery; Simon Thomas, Cyprotex Discovery Ltd

11:30 am – 12:00pm Identification of Systemic Toxicity Triggers Associated With VEGF-R Inhibitors; Hisham Hamadeh, Amgen Inc.



Job SeekersSLAS Career Connections at SBS 2011 provides job seekers a means to browse the job boards, and network with recruiting professionals.

Online Résumé Submission•

Connect With Employers Also Attending SBS 2011•

Search Jobs Available At SBS 2011•

Free! One-to-One Career Coaching Sessions•

EmployersYour company can conduct highly confidential and professional in-person interviews, and have a major presence in an informal setting that nurtures networking and relationship building. SBS 2011 posting packages are available.

Special Job Posting Rates Available for SBS 2011•

Private Interview Space Available•

Access to over 2,000 SBS 2011 participants•

Enhanced Career Coaching Services at SBS 2011•

Marshall Brown and Associates partners with •SLAS to provide FREE services

Monday – Tuesday, March 28 – 29In response to the constricting job market around the world, SLAS introduces SLAS Career Connections, Career advisor Marshall Brown, PCC, of Marshall Brown and Associates, Washington, D.C. will staff SLAS Career Connections at SBS 2011. Together with colleague Alan De Back, Marshall Brown will provide professional and discrete career services for SBS 2011 participants. Career advisors are on hand for private, one-to-one dedicated time to conduct mock interviews, review résumés, provide coaching and networking guidance, and strategize market opportunities with job seekers and hiring managers. This is a free service.

Get Started Today! Create an Account at SLAS.org/events/sbs11/careerconnections.cfm

Special Educational Sessions

Sunday, March 27, 1:00 – 4:00 pmBioAssay Ontology: Development of an Industry Standard for the Description and Categorization of Small Molecule High-Throughput Screening DataPresenters: Stephan Schürer, University of Miami; Vance Lemmon, University of Miami

Large and diverse data sets that are generated in high-throughput screening (HTS) campaigns in industry, non-profit, and academic organizations are presently difficult to explore. We have begun to develop a bioassay ontology and software tools to formalize the knowledge in HTS data sets in order to facilitate their analysis and integration with other databases. This interactive program presents the progress that has been made to date, demonstrate software that we have developed and seek feedback from the community. Individuals interested in assay standards, analysis and integration of HTS results should participate. This project is supported by a grant from the National Human Genome Research Institute.

Monday, March 28, 7:00 – 9:00 amAnalytical and Life Science Systems Association (ALSSA)This exclusive invitation-only briefing assesses several recent developments and trends in laboratory automation technologies and applications and the strategic implications for users and suppliers. Featured speakers include senior level executives from customers and users from both the pharma and food processing industries.

Tuesday, March 29, 1:15 – 2:15 pmSLAS Strategic Plan MeetingSuccessful organizations require a strategic plan founded in sound, systematic and rational principles, and supported by diligent implementation, monitoring and evaluation. As the first step in establishing results-based accountability for the future growth of SLAS, the SLAS Strategic Plan Working Group began by addressing these essential points: Where are we; what do we have to work with; where do we want to be; and how do we get there?

For the past several months, the Working Group and SLAS professional team members researched, debated, developed and ultimately documented this inaugural strategic plan. The SLAS Board of Directors then took its turn considering, discussing and debating the plan before unanimously approving it in September. As a member-driven society, however, our work is just beginning.

This plan is not a rigid step-by-step recipe of next steps. It is a multi-dimensional context that will guide our decisions and a framework to measure our progress in the months and years ahead. Because this is a major time of transition for our newly formed organization, we expect many elements and pressures to impact the organization, however, continued adherence to this plan will ensure that our focus remains true to our mission and goals.

With this in mind, members of the Strategic Plan Working Group, Board of Directors, and the professional team need to hear from you—the SLAS members. Please take advantage of this meeting opportunity to voice your ideas and perspective to help us further refine this first-ever SLAS strategic plan.

Maximize Your Conference Experience Through Effective NetworkingMonday, March 28, 8 – 9 am

Learn how to best and most effectively utilize your time by connecting with the right people at SBS 2011. This session looks at key strategies for developing personal business relationships that help you get things done, make connections and build a strong framework for your career success.


Academic OutreachChair: Sandra Nelson, University of Cincinnati

The mission of the Academic Outreach Committee is to foster greater interaction among academia, government, pharmaceutical research companies and suppliers. In keeping with that mission, the Academic Outreach SIG provides a venue for academics to meet and exchange ideas, common problems and solutions.

ADMETChair: Charles Crespi, BD Biosciences

The mission of the Absorption, Distribution, Metabolism and Toxicology SIG is to advance drug discovery and development by promoting the discussion and dissemination of principles, topics and ideas for the integration of higher throughput technologies with methods for determining toxicity, pharma-cokinetics and metabolism. The goal is to accelerate the drug-discovery pipeline and shorten the time of the development of new drugs that cure illnesses and improve quality of life. This special interest group creates a bridge and network between scientists working in the fields of preclinical research, pharmacology, pharmacokinetics and those who are the producers of combinatorial libraries.

Automation Quality ControlChairs: John Thomas Bradshaw, Artel; Jack Dawson, HighRezs Biosolutions

The Automation Quality Control SIG provides a forum for discussion of topics relating to optimizing performances of laboratory instrumentation. The objective is to encourage development of procedures that should be of interest to instrument vendors and practitioners alike.

Data and Image AnalysisChair: Chip Allee, Ceutical Soft, Inc.; Co-Chair: Mann Shoffner, SRU Biosystem

The Data and Image Analysis SIG is dedicated to sharing best practices, experiences and expertise, and to encouraging collaboration. The group will actively address issues in the area of information technology and strategies and foster discussions, information sharing and meetings among group members.

Microplate StandardsChairs: Amer El-Hage, Beeston Engineering; Michael Shanler, BD Biosciences

The Microplate Standards SIG exists to recommend, develop and maintain standards to facilitate automated processing

of microplates on behalf of and for acceptance by the American National Standards Institute (ANSI). Once such standards are approved by the MSWG, they are presented to the BSS Executive Council for approval and submission to ANSI. Participation in this SLAS working group is open to all interested parties directly and materially affected by its activities, including nonmembers of SLAS.

Sample ManagementChairs: Richard Kuo, Novartis; Timothy Dawes, Genetech, Inc.

The Sample Management SIG provides a forum for discussing sample library management issues in the modern drug-discovery high-throughput screening laboratory. Sample libraries include discrete compounds, defined compound mixtures, natural product extracts, and biologics (tissues, cells, DNA, RNA, and antibodies). Topics of critical importance include issues involved in Sample Collection; Materials Management; and Instrumentation and Laboratory Automation.

Screen Design and Assay TechnologyChair: Kenda Evans, PerkinElmer

The goals of the Screen Design and Assay SIG are to: share current best practices and experiences in the design of screens for high- and ultra high-throughput screening programs; provide a platform to encourage an open discussion among group members of any new screening technologies that can be beneficial to the screening community; encourage academic and industrial members to actively contribute to the SIG; identify any gaps in reagent(s) and instrumentation and/or in the screening environment, and seek to influence the appropriate supplier(s); and evaluate new technologies and instruments on a voluntary basis and share findings at technology-based user group meetings on a more frequent basis.

Stem Cells in Drug DiscoveryChairs: Marcie Glicksman, Harvard NeuroDiscovery Center; Sitta Sittampalam, University of Kansas Medical Center

The mission of the Stem Cells in Drug Discovery SIG is to promote the discussion and dissemination of information on new enabling technologies related to the use of stem cells and primary cells in drug discovery. We will discuss current developments in stem cell biology, human and mouse pluripotent stem cells, and reprogrammed stem cells. This group will function to create a bridge between the network of scientists working in the fields of regenerative medicine, stem cell biology, chemical biology and drug discovery.

Special Interest Groups

SBS 2011 Special Interest Groups (SIGs) are where important discussions happen. There is no fee to attend SIG meetings. For additional information on the Special Interest Groups visit SLAS.org/events/sbs11.

Tuesday, March 29, 2:00 – 4:00 pm


Poster ProgramPoster presentations are a long-standing SBS conference highlight. Participants may browse through the SBS 2011 collection of posters, located in the exhibit hall, for credible and concise examinations of new techniques and technologies from around the world. New at SBS 2011, SLAS introduces the Student Poster Competition. Twelve applicants are selected to receive the Travel Award in 2011. Of those selected, all are considered for the Student Poster Competition at SBS 2011, which offers cash awards for first, second and third place for the most outstanding poster presentation.

Exhibition

NEW Exhibit Hours for 2011!

Monday, March 28 11:00 am – 6:30 pmTuesday, March 29 12:00 pm – 4:30 pmWednesday, March 30 12:00 pm – 5:30 pm

Get up close and personal with more than 150 exhibitors with new technologies and techniques that are shaping innovation and achievement in laboratories around the world. New exhibit hours ensure more than enough time for convenient, hands-on exploration.

Don’t forget to join us for the exhibit hall receptions on Monday and Wednesday during the final hour of the SBS 2011 exhibition. It’s a great time to visit exhibitors with whom you haven’t yet connected while enjoying complimentary beverages and networking with friends and colleagues.

NEW! New Product Award (NPA) Designations at SBS 2011 to Recognize Best New Products on Exhibit Floor

In the spirit of innovative excellence, each year dozens of new products launch on the SBS exhibit floor. This year, to celebrate these breakthroughs and acknowledge the best of what’s new, the SLAS New Product Award (NPA) designation has been introduced. At SBS 2011 in Orlando, a team of experts will select up to three of the most promising new products launched on the exhibit floor for official SLAS NPA designation.


AAT Bioquest, Inc. ABS Inc.Agilent Technologies Inc.Albany Molecular Research, Inc.Amnis Corporation Art Robbins InstrumentsAxxam SpA Beckman CoulterBellBrook Labs Berthold Technologies BIOCIUS Life Sciences BioFocus BioMedTech Laboratories, Inc. Bio-Rad LaboratoriesBiostatus LTD. BioTek Instruments, Inc.Blue Sky Biotech, Inc. BMG Labtech, Inc. BPS Bioscience, Inc.BrandTech Scientific, Inc. Cayman Chemical Company CCS Cell Culture Service GmbHCell Signaling TechnologyCellectis bioresearch Cellular Dynamics International ChanTest Corp. ChemBridge Corporation Cisbio Bioassays Computype, Inc.Corning Life SciencesCYTOO Cell Architects DiscoveRx CorporationDualsystems Biotech AGEMD MilliporeEnamine Essen BioScience, Inc.Fluxion BiosciencesForteBio, Inc. GE Healthcare GenedataGenScriptGreiner Bio-OneHamamatsu Corporation HighRes BiosolutionsHorizon Discovery LtdICx Nomadics

IDBS IDEX Health and Science InSphero IntelliCyt CorporationInternational Drug DiscoveryKinaxo Biotechnologies KINOMEScan Labcyte, Inc. Lathrop Engineering Inc. LiCONiC US, Inc.Life Chemicals, Inc. Lonza Lumigen matrical bioscience MeCour Temperature Control Micronic North America, LLC Microsonic Systems MipTec 2011Molecular Devices MRC Technology Naeja Pharmaceutical Inc. Nanion Technologies GmbH Nexus Biosystems Omni International, Inc.Pall Life SciencesPerkinElmerPharmaDiagnostics NV Platypus Technologies LLC Promega Corporation reinnervate, LtdReTiSoft Inc. Roche RTS Life Science Sanford-Burnham Research InstituteSigma Life Science Specs SRU Biosystems, Inc.Tecan The Automation Partnership Titertek Instruments Inc. Titian Software Ltd TTP LabTech Viaflo CorporationWako Pure Chemical Industries Wyatt Technology Corporation

Exhibitors (as of December 8)

Exhibitor Workshops and TutorialsLearn about the science behind the technology and how to increase efficiencies in your lab. As part of the technical program, exhibiting companies will present scientific tutorials and workshops. Each of these is designed to give you an in-depth look at topics of ongoing practical interest. Attendance is free, but space is limited, so reserve your space when registering.

Workshops run three hours, and tutorials run 45 minutes.

For an up-to-date listing of companies offering tutorials and workshops, visit our website at SLAS.org/events/sbs11.

Companies Offering Exhibitor Workshops (as of December 8)

Agilent Technologies, Inc.•

Companies Offering Exhibitor Tutorials (as of December 8)

Bio-Rad Laboratories•

Cell Signaling Technology•

Cisbio Bioassays•

Corning Life Sciences•

Fluxion Biosciences, Inc. •

GE Healthcare•

Genedata•

Exhibition

PerkinElmer•

InSphero AG•

IntelliCyt Corporation•

Kinaxo Biotechnologies•

reinnervate•

Roche•

RTS Life Science•

SRU Biosystems•


General Information

Orlando, FloridaOrlando is best known as a family destination with well known attractions. However, it can also be a fun and exciting city for adults. From playing a round of golf, shopping at outlet malls, enjoying a fine-dining experience, or visiting legendary theme parks, Orlando offers a variety of activities from which to choose.

Gaylord Palms Resort & Convention Center SBS 17th Annual Conference and Exhibition held at the Gaylord Palms Resort in Orlando, Florida area located next to the Walt Disney World Resort. For reservations, visit SLAS.org/events/sbs11 or call +1.407.586.0000 and ask for the Society for Biomolecular Sciences rate.

$239 Single/Double Occupancy (plus mandatory $15 resort fee*):

This rate is available until Monday February 21, 2011, •or until the block is filled, whichever is first.

Cancellation Policy: 72 Hours prior to arrival •

Early Departures: subject to a $50 fee. Please note •that this is applicable only if you change your departure date after check in.

Gaylord Palms Resort is just 20 minutes from •Orlando International airport

The resort fee of $15 • per room, per night includes: Wireless internet access in guest rooms, atriums, and poolside; Daily newspaper; Dasani bottled water (2 replenished daily); Access to the resort’s state-of-the-art Fitness Center; High-speed internet access in each guest room; Local phone calls up to 20 minutes ($.10/minute thereafter); Toll-free and credit card calls up to 20 minutes ($.10/minute thereafter); Scheduled transportation to Walt Disney World theme parks.

Deposit:

The Gaylord Palms Resort and Convention Center •requires a credit card guarantee at the time of reservation.

Changes and Cancellations:

All reservation changes and cancellations must be made •through Gaylord Palms Resort and Convention Center.

To avoid being charged for one night, cancellations •must be made at least 72 hours prior to your arrival date. Early departures are subject to a $50 fee. Please note that this is applicable only if you change your departure date after check in.

Group Hotel Reservations:

Group hotel reservations are available, for more •information visit SLAS.org/events/sbs11.


General Information

Airline ReservationsYou may book your air travel directly with SBS 2011’s official travel agent, National Travel at 800.557.0842.

Child CareKid’s Nite Out is Central Florida’s number one choice for professional childcare at all hotels, resorts and vacation homes. Contact Shani Thompson for additional information: +1.407.828.0987; www.kidsniteout.com

Discounted Theme Park TicketsBring your family to Orlando and enjoy special discounts on admission tickets to the major theme parks. Whether you’re planning on arriving before the conference starts or staying after the conference ends, these tickets will save you time and money. To purchase tickets, visit SLAS.org/events/sbs11.

Registration HoursRegistration will be located on lower level of the Gaylord Palms Convention Center, in front of the Exhibit Hall. Badges and meeting materials can be picked up during the following times:

Saturday, March 26 2:00 – 7:00 pm

Sunday, March 27 7:00 am – 5:00 pm

Monday, March 28 8:00 am – 6:30 pm

Tuesday, March 29 8:00 am – 5:00 pm

Wednesday, March 30 8:00 am – 5:30 pm

Thursday, March 31 8:00 – 11:00 am

Social Events and NetworkingMonday, March 28, 5:00 – 6:00 pm

Welcome Reception in the Exhibit Hall•

Join our manufacturing representatives in the exhibit hall for hors d’ouevres and complimentary beverages, network with peers, and visit with exhibitors.

Wednesday, March 30, 4:30 – 5:30 pmExhibit Hall Reception•

Visit exhibitors while enjoying complimentary beverages and networking with friends and colleagues.

Wednesday, March 30, 7:00 – 10:00 pmConference Networking Reception•

Join your colleagues after dinner poolside at the Gaylord Palms for a “Key West Night.” Desserts and drinks are provided.

SLAS Creates Smart-Savers Discount Program for SBS 2011—Extraordinary Discounts for Registration and Travel

Whether you are focused on continuing education and learning the latest about drug discovery and screening, want to see and touch the newest technologies hitting the research marketplace from around the world, or need to connect in a meaningful, face-to-face way with a colleague—SBS 2011 has everything you need. Spend a few moments reading about and then take advantage of the following cost-saving programs we have developed for you. Join us at SBS 2011.

“Take Off With Us” Flight Discount ProgramThe “Take Off With Us” flight discount program was created to help diminish the financial impact of travel costs for individuals interested in exploring drug discovery and screening at SBS

2011. This mission-centric program provides $200 off the first 50 airline tickets purchased by full-conference paid registrants. The discount applies to any airline available through the official SBS 2011 Travel Agent.

Early-Bird RegistrationAn easy way to secure significant savings for SBS2011 is to register early. Not only does it give you extra time to prepare for our industry-leading conference, it gives you an opportunity to save up to $200 on your registration. Register by January 24, 2011 to take advantage of maximum Early-Bird registration rates.

Discounted Registration for GroupsSLAS offers discounted registration to groups attending SBS 2011. Group discounts are only applicable to full-conference registration fees and all registrations must be received by the registration department together and from the same company/location. Group discounts of 20% per registrant are available for groups of five. This discount program is only available to registrants who pre-register and will not be available on-site.

Academic Registration WaiverThe Academic Registration Waiver was created to diffuse some of the financial pressure currently impacting the academic community. The Waiver provides complimentary conference registration to professors and associate professors who attend SBS 2011 with at least two pre-registered students. Student registration for the five-day event is only $25.

Unemployment Registration WaiverAn Unemployment Registration Waiver is being offered to provide complimentary SBS 2011 registration to those currently unemployed. There is no better way to kick-start your career and job search than to immerse yourself in career advancement and search tools, as well as take advantage of numerous professional development and networking opportunities.

Learn more about the Smart-Savers Discount Program at SLAS.org/events/sbs11.


SBS 2011 Registration Form

Three Ways to Register:Online—Visit SLAS.org/events/sbs11

Mail—Remit payment with this form to:SLAS, 11260 Roger Bacon Dr. # 500, Reston, VA 20190, USA

Fax—Send this form with complete payment information to:+1.703.964.1246

Attendee Information:Please print clearly or type:c Dr. c Mr. c Mrs. c Ms. c Miss

Name

Affiliation

Title

Department

Address

City State

Zip Country

Telephone Fax

Email

c Please check this box if you do not wish to be a part of the SBS mailing list.

Education:c AAS c BS c MS c MD c PhD c Other

Current Lab Automation Sector: (check only one)

c Academic c Consulting c Government

c Industry c Technology Provider c Other

Industry in Which Company Operates: (check only one)

c Agriculture c Clinical Diagnostics

c Consumer Products c Drug Discovery

c Drug Development c Energy Generation and Petrochemicals

c Forensics and Security c Food

c Other

Purchasing Involvement: (check only one)

c Approver/Final Decision Maker

c Not involved in buying decisions

c Specifier c Influencer c Other

Classify Your Current Position: (check only one)

c Account Executive c Administrative

c Attorney/Legal c Consultant

c Director c Editor/Reporter

c Intern c Lab Specialist

c Lab Technician c Manager

c President/CEO c Professor

c Retired c Sales/Marketing

c Scientist/Engineer/Researcher

c Student c Vice President

Primary Area of Interest: (check only one)

c Bar Code Technology

c Biostatistics and Exploratory Data Analysis

c Design of Experiments (DOE)

c Electronic Laboratory Notebooks

c Information Technology for the Laboratory

c Mass Spectrometry

c Microarray Applications

c Liquid Handling

c Microfluidics

c Molecular Diagnostics

c Nanobiotechnology

c Patents

c Pharmacogenomics

c Project Management

c Other

Short Courses:Please choose only one. Short courses are an additional cost, see page 22 for pricing:c Automated Assays for Drug Discovery:

A Toolbox Approach to Selecting an Appropriate Assay

c BacMam101: Practical Aspects of Making and Using BacMam Vectors

c Establishing Cell-Based Assays for Screening

c In Vitro ADME Screening: Basic Concepts and Practical Methods

c Label-Free/Biophysics Methods for Screening

c Statistical Methods for In Vitro Assays in Drug Discovery

c High-Content Screening

Please visit SLAS.org/events/sbs11 for more information on SBS 2011 Short Courses.


Registration Fees & Pricing*

Full Conference Early Member Discount

(Ends 1/24/11)

Full Conference Advance Registration

(Ends 2/21/11)

Full Conference Late Registration

Short Course (Indicate course on page 21)

Member $895 $1095 $1295 $550

StudentPlease fax student ID

to +1.703.964.1246$25 $25 $25 $265

$1375 $1375 $1575 $675Non-Member

$349 $449 $549 $265Gov/Academic Member

$549 $549 $699 $340Gov/Academic Non-Member

Cancellation PolicyCancellation requests received prior to Friday, February 25, 2011 will be refunded in full, less a $50 processing fee. No refunds will be issued after this date. Cancellations must be submitted in writing to SLAS Registration at 11260 Roger Bacon Dr., #500, Reston, VA 20190, via fax at +1.703.964.1246 or via email to [email protected]. Please note that all refunds will be issued by check. All cancellations will be processed and refunds distributed within 30 days of the close of the conference. Registrants may substitute another individual from within the same company and pay any difference in registration type. SLAS must be notified in writing of any substitutions.

c I agree to all terms and conditions listed below:In Case of Emergency This year we are asking that you please provide your cell phone number: . This number will only be used in the event of an emergency. It will not be used for marketing purposes or stored in any way. Should an emergency arise you will receive a text message sent to the number you’ve provided.

Publicity ReleaseI acknowledge that at times during the SBS 2011 conference, sessions will be presented before a live audience and SLAS may web-cast, videotape, audiotape, photograph, record or broadcast SBS 2011 or various aspects of SBS 2011. I hereby grant full permission to SLAS to use any photograph, videotape, audiotape, motion picture, or any other similar recording or broadcast of SBS 2011 including my name and likeness for any SLAS business purpose.

SLAS Liability WaiverI, as a conference participant, agree and acknowledge that I am undertaking such participation in SLAS events and activities of my own free will. I hereby assume all risks of personal injury and/or other loss or damage arising out of or in any way associated with my participation in this conference. I release to the fullest extent permitted by law, SLAS and any of its directors, officers, employees, volunteers, contractors, agents or other representatives, successors, assigns, and all others acting on their behalf (collectively referred to herein as the “Released Parties”) from any and all responsibilities, claims, expenses, personal injury, wrongful death or liability for injuries or damages, and expenses, including reasonable attorney’s fees and costs incurred in defending such claims directly or indirectly resulting from, or in any way arising out of or related to my participation in this conference. I acknowledge that my participation in this conference is expressly conditioned on my agreeing to the foregoing.

Method of Payment:Check Number: Check Amount: Please make checks payable to SLAS; Send form to: 11260 Roger Bacon Dr. #500, Reston, VA 20190, USA

Credit Card: c Visa c Mastercard c Discover c AMEX

Name on Credit Card: Card Number:

Exp. Date: Authorized Amt.: Signature:

Billing address if different than above:

Name on Card:

Address: City:

State: Zip/Postal Code: Country:

Free Free Free Free

SBS 2011 Registration Form (continued)

One-Day Exhibit Hall Only

(registration required)

Conference Proceedings CD: c Member $99 c Non Member $149* Discounted Registration for Groups: SLAS offers discounted registration to groups attending SBS 2011. Group discounts are only applicable to full-conference registration fees and all registrations must be received by the registration department together and from the same company/location. Group discounts of 20% per registrant are available for groups of five. This discount program is only available to registrants who pre-register and will not be available on-site. Visit SLAS.org/events/sbs11.

Please circle applicable fee


SBS 2011 Scientific Committee

Program Chairs

Paul Bernasconi, Ph.D. BASF Corporation

Peter Hodder, Ph.D. The Scripps Research Institute

Roger Bosse, Ph.D., PerkinElmer

Paul Burn, Ph.D., Sanford Project

Sabrina Corazza, Ph.D., Axxam SpA

Claude DuFresne, Ph.D., Merck

Ken Duncan, Ph.D., Bill and Melinda Gates Foundation

Achim Grenz, Ph.D., F. Hoffmann-La Roche Ltd

Bob Hertzberg, Ph.D., GlaxoSmithKline

Keith Houck, Ph.D., Environmental Protection Agency

Jim Inglese, Ph.D., NIH Chemical Genomics Center

Bill Janzen, Ph.D., University of North Carolina at Chapel Hill

Scott Martin, Ph.D., St. Louis University

Jonathan O’Connell, Ph.D., Bristol-Myers Squibb Company

Ulrich Schopfer, Ph.D., Novartis Institutes for BioMedical Research

Daniel Sipes, Ph.D., Genomics Institute of the Novartis Research Foundation

Andrew Su, Ph.D., Genomics Institute of the Novartis Research Foundation

Phil Tagari, Ph.D., Amgen

SLAS Board of DirectorsMichelle Palmer, Ph.D., Broad Institute of Harvard and MIT

Jason Abbas, M.S., Syngenta Seeds

Robert Ames, Ph.D., GlaxoSmithKline

David Dorsett, M.B.A., Bristol-Myers Squibb Company

Bill Janzen, Ph.D., University of North Carolina - Chapel Hill

Jeff Paslay, Ph.D., Paslay Consulting

Erik Rubin, Ph.D., Bristol-Myers Squibb Company

Mary Jo Wildey, Ph.D., Merck Research Labs

Andy Zaayenga, Ph.D., HighRes Biosolutions

Biomolecular Sciences Section (BSS) Executive CouncilJohn Printen, Ph.D., Life Technologies

Roger Bosse, Ph.D., PerkinElmer

Sue Holland-Crimmin, Ph.D., GlaxoSmithKline

Lorenz Mayr, Ph.D., Novartis Pharma

Steve Rees, Ph.D., GlaxoSmithKline

Melvin Reichman, Ph.D., Lankenau Institute for Medical Research Chemical Genomics Center

John Wang, Ph.D., Wang Consulting

Maria Webb, Ph.D., Venenum Biodesign

Andy Zaayenga, Ph.D., HighRes Biosolutions

Laboratory Automation Section (LAS) Executive CouncilMalcolm Crook, Ph.D., Process Analysis & Automation, Ltd.

Jason Abbas, M.S., Syngenta Seeds

Chris Detter, Ph.D., Los Alamos National Laboratory

Hansjörg Haas, Ph.D., Thermo Fisher Scientific

R. Scott Martin, Ph.D., Saint Louis University

Robyn Rourick, M.S., Genentech

Craig Schulz, Ph.D., Amgen

Nitin Sood, M.S., Agilent Technologies

Kerstin Thurow, Ph.D., Center for Life Science Automation University of Rostock

Scientific Committee and SLAS Leadership

Thank You to the Sponsors/Media Partners of SBS 2011!

Bronze Sponsors:

Media Partners:

Conference Sponsors:

100 Illinois Street, Suite 242 St. Charles, IL 60174 USA SLAS.org

Presorted StandardU.S. PostagePAIDPermit No. 9711Chicago, IL

slas sbs orlandoconference prelim program

Documents